Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients

Inclusion Criteria: * Age≥18 years, ≤75 years, male or female * Advanced renal cellcarcinoma is diagnosed histologically or pathologically * 1st line treatment of Sunitinib and 2nd line treatment of Everolimus and no more systemic anti-angiogenesis targeted drug therapy * Have at least one measurable tumor lesion (Response Evaluation Criteria In Solid Tumors) * Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1 * The expected life span is ≥12 weeks * No contraindications for chemotherapy, with enough liver function and renal function and normal ECG recording Peripheral hemogram: neutrophil≥1.5×109/L, Plt≥100×109/L, Hgb≥90g/L Renal function: serum creatinine≤1.5 folds the upper limit of normal (ULN) For patients with non-metastatic liver dysfunction:alanine aminotransferase and aspartate aminotransferase≤2.5 ULN, For patients with metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤5 ULN * The patients participate voluntarily and have signed the informed consent form Exclusion Criteria: * Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures * Patients with severe acute infection without being controlled effectively or having pyogenic and chronic infections with persistently unhealed wounds * Past history of serious heart diseases, including: cardiac function classification ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled hypertension * Patients with a history of HIV infection or active phase of chronic hepatitis B/C * negative imaging examination result 4 weeks prior to enrollment) * Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs) * A history of allogeneic organ transplantation * Patients with evidence of hemorrhagic constitution or a past history of hemorrhage * Patients currently receiving renal dialysis * Past or present concomitant tumors with the primary lesions or histological characteristics different from the tumors evaluated in this study, excluding other tumor cured longer than 3 years before enrollment * Patients participating in other clinical trials simultaneously * Other conditions unsatisfying the inclusion criteria in the investigator's opinions